Report Overview
Nicotinamide mononucleotide (NMN) is a molecule that has gained attention in recent years for its potential health benefits.
NMN is a precursor of nicotinamide adenine dinucleotide (NAD+), a coenzyme that plays a crucial role in energy metabolism, DNA repair, and cellular aging.
Studies in animals have shown that supplementing with NMN can increase NAD+ levels and improve markers of health and longevity.
NMN has been studied for its potential benefits in various conditions, including age-related decline, cardiovascular disease, and neurodegenerative disorders.
NMN is available as a dietary supplement in some countries, including the United States, but its safety and effectiveness in humans is still being studied.
Some researchers have raised concerns about the potential side effects of NMN supplementation, such as increased risk of cancer or liver toxicity.
Market Analysis
The Global Nicotinamide Mononucleotide (NMN) Market , valued at US$ 360.37 million in 2023, is projected to reach US$ 762.61 million by 2030. Experiencing a robust CAGR of 10.9% during the forecast period 2024-2030.
